Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is well-positioned for future growth with its groundbreaking Deep TMS platform technology, which has shown impressive remission and response rates in treating mental health disorders. The recent FDA approval for the at-home use of the ProlivRx system shows strong potential for expanded market access and reimbursement, while the accelerated SWIFT protocol offers a significantly faster and more convenient treatment option for patients. With a strong financial position and a promising market outlook, BrainsWay is expected to continue driving adoption and making a positive impact in the field of interventional psychiatry.

Bears say

BrainsWay is a medtech firm with solid operating performance and a positive medium- to long-term outlook, indicated by its recent full-year financial results and the expected growth in revenue for the next two years. However, the company's stock may face challenges due to the recent change in the ratio of American Depositary Shares to ordinary shares, which has resulted in a decreased 12-month price target of $15 from $30 per share. Additionally, there are certain risks to consider, such as slow uptake of their products, difficulty in expanding reimbursement and market access, and potential dilution risk.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.